Latest studies
- RecruitingPHASE3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study looks at a new medicine, Maridebart cafraglutide, for people with heart failure and obesity. It aims to see if the medicine can reduce heart-related problems like hospital stays, improve symptoms, and help people live longer, alongside their usual heart failure care.
Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesityHong Kong - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaHong Kong - Active not recruitingPHASE3
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This study looks at a medicine called atezolizumab for people with a type of bladder cancer that has spread into the muscle. It checks if this medicine, given after surgery, can stop the cancer from coming back in those who show signs of tiny cancer cells in their blood.
Muscle-invasive Bladder CancerHong Kong - Active not recruitingPHASE3
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.
Myeloproliferative DisordersMyelofibrosisPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisHong Kong - Active not recruitingPHASE3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
This study is testing a new medicine, ianalumab, for adults with active lupus nephritis. It compares ianalumab given every 4 or 12 weeks to a dummy medicine, alongside standard treatments, to see if it's safe and effective.
Lupus NephritisHong Kong - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Hong Kong - Active not recruitingPHASE3
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
This study is looking into a new combination of medicines for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It compares a new medicine combination with a standard one to see if the new option works better.
Relapsed or Refractory Multiple MyelomaHong Kong - RecruitingPHASE3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This study looks at a new combination of drugs, adagrasib, pembrolizumab, and chemotherapy, for people with a specific type of advanced non-small cell lung cancer (NSCLC) that hasn't been treated before and has a KRAS G12C gene change.
Carcinoma, Non-Small-Cell LungHong Kong - RecruitingPHASE3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
This study is looking at a new treatment called AAA817, combined with standard prostate cancer drugs, for men with advanced prostate cancer. It compares this new combination to existing treatments to see which works best at slowing the cancer's growth.
Prostate CancerHong Kong - Active not recruitingPHASE3
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
This study, KRYSTAL-10, is for people with advanced bowel cancer that has a specific genetic change (KRAS G12C). It compares a combination of new drugs, MRTX849 and cetuximab, against standard chemotherapy to see which works better for those who have already had initial treatment.
Advanced Colorectal CancerMetastatic Colorectal CancerHong Kong - RecruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
Non-small Cell Lung Cancer (NSCLC)Hong Kong - RecruitingPHASE3
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
This study looks at a new medicine, pelacarsen, for people with heart and circulation problems and high levels of a specific fat called Lp(a). It aims to see if it's safe and effective when used alongside another medicine, inclisiran.
Atherosclerotic Cardiovascular Disease (ASCVD)Hong Kong - Not yet recruitingNA
Direct Warming Frozen Embryo Transfer Outcomes in Assisted Reproductive Technology
This study looks at a new, quicker way to thaw frozen embryos for IVF. It compares a 'direct warming' method to the usual one, hoping to improve success rates for pregnancy and live births. Researchers want to see if the new method is better and more cost-effective for women aged 18-45.
Frozen Embryo Transfer (FET)Assisted Reproductive TechniquesIn Vitro Fertilization (IVF)Cryopreservation of EmbryosHong Kong - Active not recruitingPHASE3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
This study is looking at a new medicine called frexalimab for people aged 18-55 with certain types of Multiple Sclerosis (MS). It compares frexalimab to an existing MS medicine, teriflunomide, to see how well it stops MS relapses and if it's safe.
Multiple SclerosisHong Kong - RecruitingPHASE2
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
This study is looking at a new medicine called iptacopan for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see how well it works and if it's safe when added to standard treatments.
Lupus NephritisHong Kong - RecruitingPHASE3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
This 52-week study is testing a new drug, depemokimab, for adults with uncontrolled Hypereosinophilic Syndrome (HES). It aims to see if depemokimab is effective and safe compared to a placebo, alongside their usual HES treatment.
Hypereosinophilic SyndromeHong Kong - RecruitingPHASE3
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
This study is an extension of a previous trial for people with a condition called hereditary angioedema (HAE). It's looking at the long-term safety and how well a medicine, ADX-324, works for HAE types 1 and 2. Participants would have already taken part in the earlier study.
Hereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2HAEHong Kong - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
This study is testing a new medicine, Pegozafermin, for people with a severe liver condition called MASH with cirrhosis. It will check how well the medicine works and if it's safe compared to a dummy medicine.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated CirrhosisHong Kong - Active not recruitingPHASE3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments, Iberdomide and Lenalidomide, after a stem cell transplant for multiple myeloma. It aims to find out which one works better at keeping the cancer under control following initial treatment.
Multiple MyelomaHong Kong - Active not recruitingPHASE3
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
This study looks at a new medicine called survodutide for people who are overweight or obese. It checks if survodutide helps with heart health problems. Participants take the medicine weekly for up to 2 years, alongside diet and exercise advice.
ObesityHong Kong - RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)Hong Kong - Active not recruitingPHASE3
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
This study looks at a medicine called nivolumab for liver cancer. It's for people who've had surgery or other treatment to remove their cancer, but are at high risk of it coming back. We want to see if nivolumab can stop the cancer from returning.
Hepatocellular CarcinomaLiver CancerHong Kong - Active not recruitingPHASE2
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
This study looks at a new drug, ALG-000184, for chronic hepatitis B. It compares it with an existing treatment, tenofovir, to see how safe and effective it is over 48 weeks. It's for adults who haven't been treated for hepatitis B before.
Chronic Hepatitis B InfectionHong Kong - RecruitingPHASE3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
This study is testing a new drug, firmonertinib, for advanced non-small cell lung cancer with specific genetic changes. It compares firmonertinib to existing treatments to see which works best and is safest for newly diagnosed patients.
Non-Small-Cell Lung CancerMetastatic Non-Small-Cell Lung CancerAdvanced Non-Small-Cell Lung CancerEGFR P-Loop and Alpha C-Helix CompressingHong Kong - RecruitingPHASE3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
This study offers ongoing treatment with pelacarsen for people who have finished a previous trial for heart disease. It aims to check the long-term safety of the medicine, which helps lower a type of cholesterol called Lp(a).
Cardiovascular Disease and Lipoprotein(a)Hong Kong - Active not recruitingPHASE3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
This study is testing a new medicine, inclisiran, to see if it can prevent serious heart problems like heart attacks and strokes in people who are at high risk but haven't had one before. They are comparing it to a dummy medicine.
Primary Prevention of Atherosclerotic Cardiovascular DiseaseHong Kong - Active not recruitingPHASE2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
This study is for people with advanced solid cancers that haven't responded to other treatments. It uses a "precision medicine" approach, matching treatments to the specific genetic changes found in each person's tumour, aiming for more effective and personalised care.
Solid TumorsHong Kong - Active not recruitingPHASE1, PHASE2
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This study is for children and teenagers with solid tumours or brain tumours that are advanced or have spread, and for whom standard treatments haven't worked or aren't suitable. It's testing a new medicine called Entrectinib to see if it's safe and effective.
Solid TumorsCNS TumorsHong Kong - Active not recruitingPHASE3
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This study, called POSEIDON, is testing new drug combinations for people with a type of lung cancer called non-small cell lung cancer (NSCLC). It's comparing usual chemotherapy with combinations of two new drugs, durvalumab and tremelimumab, to see if they work better.
Non Small Cell Lung Cancer NSCLCHong Kong - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This study is looking at new ways to treat advanced kidney cancer that hasn't been treated before. It combines three medicines to see if they work better together than two, aiming to help people live longer and keep their cancer from growing.
Renal Cell CarcinomaHong Kong - Active not recruitingPHASE2, PHASE3
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
This study looks at a new drug, Inavolisib, combined with standard treatments (Palbociclib and Fulvestrant) for a specific type of advanced breast cancer. It compares this new combination to the standard treatments alone, checking how well it works and if it's safe.
Breast CancerHong Kong - Active not recruitingPHASE3
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
This study is testing a new medicine called olpasiran to see if it can help people with heart disease and high levels of a specific fat in their blood, called Lp(a). We want to find out if olpasiran can lower the risk of heart attacks and other heart problems.
Atherosclerotic Cardiovascular DiseaseHong Kong - RecruitingPHASE3
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
This study is looking at a new medicine called ADX-324 for people with Hereditary Angioedema (HAE) Type 1 or 2. It will check if the medicine helps prevent HAE attacks and if it is safe. Researchers will also look at how it affects quality of life.
Hereditary AngioedemaHAEHereditary Angioedema - Type 1Hereditary Angioedema - Type 2Hong Kong - Active not recruitingPHASE3
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study looks at a new drug, trastuzumab deruxtecan, for people in the UK with HER2-positive stomach or food pipe cancer. It compares this drug to standard treatments for patients whose cancer has grown despite previous therapy. The aim is to see if the new drug works better and is safe.
Gastric Cancer, AdenocarcinomaGastroesophageal Junction AdenocarcinomaHong Kong - Active not recruitingPHASE2
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
This study is looking at a new medicine called Redasemtide for people who have recently had a stroke. It wants to see if the medicine is safe and if it helps people get better after a stroke.
Acute Ischemic StrokeHong Kong - Active not recruitingPHASE2
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
This study is for people with cancer that has spread, who are already benefiting from a specific medicine called trastuzumab emtansine (T-DM1) or other similar treatments in an earlier study. It allows them to keep receiving these important treatments for longer to see if they continue to help.
Neoplasm MetastasisHong Kong - RecruitingPHASE3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
This study looks at a new drug, DMX-200, for people aged 12 to 80 with a kidney condition called FSGS. It aims to see if the drug is safe and helps prevent kidney damage when taken with another medicine called an ARB.
FSGSHong Kong - Active not recruitingPHASE3
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
This study looks at new drug combinations for bladder cancer that has spread into the muscle. It compares them to standard treatment for people who can't take or don't want cisplatin chemotherapy before surgery to remove their bladder. The aim is to find more effective and safe options.
Muscle Invasive Bladder CancerHong Kong - Active not recruitingPHASE2
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called emvistegrast for people with moderate to severe ulcerative colitis. It aims to see if emvistegrast can help improve their symptoms compared to a dummy medicine.
Ulcerative ColitisHong Kong - Active not recruitingPHASE1
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
This study looks at new drug combinations for treating advanced stomach, bile duct, and pancreatic cancers. It focuses on cancers with a specific genetic change (MTAP-deletion) to see how safe and effective these new treatments are.
Advanced Gastrointestinal, Biliary Tract, and Pancreatic CancersHong Kong - RecruitingNA
ELEVATE-HFpEF Clinical Study
This study looks at whether a special type of pacemaker can help people with a common heart condition called heart failure with preserved ejection fraction (HFpEF). It aims to see if personalising the pacemaker's settings improves symptoms and quality of life.
Heart Failure With Preserved Ejection Fraction (HFpEF)Hong Kong - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
This study compares a new drug called belzutifan with an existing drug, everolimus, for people with advanced kidney cancer. We want to see if belzutifan can stop the cancer from growing for longer and help people live longer than everolimus.
Carcinoma, Renal CellHong Kong - Active not recruitingPHASE3
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
This study is testing a new drug, MRTX849 (adagrasib), for advanced lung cancer with a specific gene change (KRAS G12C). It compares it to a standard treatment, docetaxel, for people whose cancer has already been treated.
Metastatic Non Small Cell Lung CancerAdvanced Non Small Cell Lung CancerHong Kong - Active not recruitingPHASE3
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
This study is looking at a new medicine called acalabrutinib for chronic lymphocytic leukaemia (CLL). It compares acalabrutinib to usual treatments to see which works best for people whose CLL has come back or hasn't responded to previous treatment.
Chronic Lymphocytic LeukemiaHong Kong - Active not recruitingPHASE1, PHASE2
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
This study is looking at new combinations of immunotherapy drugs for people with advanced lung cancer. It combines an existing drug, Cemiplimab, with one of three new drugs (S095018, S095024, or S095029) to see which combination is safe and works best.
Non-small Cell Lung Cancer (NSCLC)Hong Kong - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
This study tested new drug combinations for advanced oesophageal cancer. It looked at pembrolizumab with lenvatinib and chemotherapy, versus pembrolizumab and chemotherapy, to see which worked best and was safest. The study has now stopped, with no safety concerns being the reason.
Metastatic Esophageal Squamous Cell CarcinomaHong Kong - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast NeoplasmsHong Kong - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesHong Kong - RecruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This study looks at a new drug combination, sacituzumab tirumotecan and pembrolizumab, for a type of breast cancer called triple-negative. It's for patients who had initial treatment but still have some cancer cells after surgery. We want to see if this new combination helps prevent the cancer from coming back better than standard care.
Triple-Negative Breast CancerHong Kong - RecruitingPHASE3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
This study is for people with advanced bowel cancer that has spread and has a specific gene change called KRAS p.G12C. It compares a new combination of treatments to standard treatment to see if it can better stop the cancer from growing.
Metastatic Colorectal CancerHong Kong